. 2018 Nov 19;7(12):1415–1423. doi: 10.1530/EC-18-0381
This work is licensed under a Table 2.
Cancer incidence in patients with type 2 diabetes, Shanghai, China, 2002–2014.
| Men (N = 24,124) | Women (N = 27,200) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of cases | Person-years | CIRa (95% CI) (/100,000) | ASRb (/100,000) | SIRc (95% CI) | No of cases | Person-years | CIRa (95% CI) (/100,000) | ASRb (/100,000) | SIRc (95% CI) | |
| All cancers | 1468 | 151,288 | 970.3 (921.9, 1021.3) | 345.0 | 0.93 (0.88, 0.98) | 1452 | 174,066 | 834.2 (792.3, 878.2) | 476.3 | 1.07 (1.01, 1.12) |
| Site-specific cancersd | ||||||||||
| Stomach | 198 | 154,078 | 128.5 (111.8, 147.7) | 42.6 | 0.63 (0.56, 0.70) | 107 | 177,585 | 60.6 (49.9, 72.8) | 25.5 | 0.90 (0.73, 1.06) |
| Colon | 152 | 154,082 | 98.6 (84.1, 115.6) | 32.8 | 1.21 (1.02, 1.40) | 155 | 177,465 | 87.3 (74.6, 102.2) | 26 | 1.20 (1.01, 1.38) |
| Rectum | 92 | 154,220 | 59.7 (48.6, 73.2) | 20.6 | 0.97 (0.77, 1.17) | 74 | 177,601 | 41.7 (33.1, 52.3) | 12 | 0.97 (0.74, 1.19) |
| Liver | 126 | 154,311 | 81.7 (68.6, 97.2) | 28.0 | 0.98 (0.82, 1.16) | 53 | 177,761 | 28.8 (22.8, 39.0) | 8.7 | 0.77 (0.56, 0.97) |
| Pancreas | 74 | 154,432 | 47.9 (38.1, 60.2) | 15.2 | 1.09 (0.84, 1.33) | 75 | 177,742 | 42.2 (33.6, 52.9) | 40.9 | 1.18 (0.91, 1.45) |
| Lung | 264 | 154,127 | 171.3 (151.8, 193.3) | 53.1 | 0.67 (0.59, 0.76) | 166 | 177,604 | 93.5 (80.3, 108.8) | 27.8 | 0.82 (0.70, 0.94) |
| Breast | 272 | 176,778 | 153.9 (136.2, 172.9) | 101.6 | 1.34 (1.18, 1.50) | |||||
| Corpus uteri | 53 | 177,604 | 29.8 (22.8, 39.1) | 14.5 | 1.07 (0.73, 1.41) | |||||
| Prostate | 134 | 154,074 | 86.9 (73.4, 103.0) | 23.5 | 1.11 (0.92, 1.30) | |||||
| Thyroid | 22 | 154,431 | 14.2 (9.4, 21.6) | 8.6 | 1.07 (0.63, 1.52) | 119 | 177,458 | 67.1 (56.0, 80.0) | 73.7 | 1.55 (1.27, 1.82) |
aCIR, crude incidence rate; bASR, age-standardized rate based on the World Standard Population; cSIR, standard incidence ratios; dordered by ICD-O code of each cancer.